JP2012520890A - 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法 - Google Patents

経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法 Download PDF

Info

Publication number
JP2012520890A
JP2012520890A JP2012500945A JP2012500945A JP2012520890A JP 2012520890 A JP2012520890 A JP 2012520890A JP 2012500945 A JP2012500945 A JP 2012500945A JP 2012500945 A JP2012500945 A JP 2012500945A JP 2012520890 A JP2012520890 A JP 2012520890A
Authority
JP
Japan
Prior art keywords
pharmaceutical
antiarrhythmic
class
antiarrhythmic agent
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012500945A
Other languages
English (en)
Japanese (ja)
Inventor
カルロス エー． シュラー，
ランガチャリ ナラシマン，
Original Assignee
インカーダ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インカーダ セラピューティクス， インコーポレイテッド filed Critical インカーダ セラピューティクス， インコーポレイテッド
Publication of JP2012520890A publication Critical patent/JP2012520890A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012500945A 2009-03-18 2010-03-18 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法 Withdrawn JP2012520890A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21038209P 2009-03-18 2009-03-18
US61/210,382 2009-03-18
PCT/US2010/027740 WO2010107964A1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015149197A Division JP2015193657A (ja) 2009-03-18 2015-07-29 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法

Publications (1)

Publication Number Publication Date
JP2012520890A true JP2012520890A (ja) 2012-09-10

Family

ID=42739985

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012500945A Withdrawn JP2012520890A (ja) 2009-03-18 2010-03-18 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2015149197A Withdrawn JP2015193657A (ja) 2009-03-18 2015-07-29 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2017123029A Pending JP2017160268A (ja) 2009-03-18 2017-06-23 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2018204914A Active JP6715305B2 (ja) 2009-03-18 2018-10-31 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2019162836A Active JP7071949B2 (ja) 2009-03-18 2019-09-06 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015149197A Withdrawn JP2015193657A (ja) 2009-03-18 2015-07-29 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2017123029A Pending JP2017160268A (ja) 2009-03-18 2017-06-23 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2018204914A Active JP6715305B2 (ja) 2009-03-18 2018-10-31 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2019162836A Active JP7071949B2 (ja) 2009-03-18 2019-09-06 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法

Country Status (9)

Country Link
US (5) US8974828B2 (enExample)
EP (3) EP2413902B1 (enExample)
JP (5) JP2012520890A (enExample)
AU (1) AU2010226613B2 (enExample)
CA (2) CA2835771C (enExample)
DK (1) DK2413902T3 (enExample)
ES (3) ES3036464T3 (enExample)
PL (1) PL2413902T3 (enExample)
WO (1) WO2010107964A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015183006A (ja) * 2014-03-25 2015-10-22 リン, シン−ユンLin, Hsin−Yung 心疾患を治療するための吸入式医薬組成物及びその調製法
JP2019509985A (ja) * 2016-02-01 2019-04-11 インカーダ セラピューティクス， インコーポレイテッド 心房細動を含む心不整脈を管理するための吸入薬物療法との電子的監視の組み合せ
JP2020519628A (ja) * 2017-05-10 2020-07-02 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
JP2021526900A (ja) * 2018-06-05 2021-10-11 インカーダ セラピューティクス， インコーポレイテッド エアロゾルを用いるブルガダ症候群の診断方法
JP2022533477A (ja) * 2019-08-01 2022-07-22 インカーダ セラピューティクス， インコーポレイテッド 抗不整脈製剤
JP2024502236A (ja) * 2020-12-17 2024-01-18 インカーダ セラピューティクス， インコーポレイテッド 心房性不整脈を有する対象におけるカルディオバージョンの誘導のためのキットおよび方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA3114582A1 (en) 2010-12-22 2012-06-28 Syqe Medical Ltd. Method and system for drug delivery
US9713687B2 (en) 2012-08-21 2017-07-25 Philip Morris Usa Inc. Ventilator aerosol delivery system with transition adapter for introducing carrier gas
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
PL3160565T3 (pl) * 2014-06-30 2022-01-10 Syqe Medical Ltd. Urządzenia i systemy do dopłucnego dostarczania środków aktywnych
CN106604755B (zh) 2014-06-30 2020-08-11 Syqe医药有限公司 流量调节的吸入器装置
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
ES2778673T3 (es) * 2015-04-14 2020-08-11 Milestone Pharmaceuticals Inc Sales altamente solubles de un inhibidor de los canales de calcio de fenilalquilamina de corta acción y usos de las mismas
ES2874087T3 (es) 2016-01-06 2021-11-04 Syqe Medical Ltd Tratamiento terapéutico con dosis bajas
WO2019183470A2 (en) * 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
WO2019241597A1 (en) * 2018-06-14 2019-12-19 Cornell University Compositions and methods for providing cardioprotective effects
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11344518B2 (en) * 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042467A1 (de) * 2005-10-10 2007-04-19 Boehringer Ingelheim International Gmbh Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2008066745A1 (en) * 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
SE408265B (sv) 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
JP3202705B2 (ja) * 1987-11-06 2001-08-27 リサーチ ディベロップメント ファンデーション 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子
US4962095A (en) * 1989-02-15 1990-10-09 E. R. Squibb & Sons, Inc. Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
JP3388896B2 (ja) 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
DE69814428T2 (de) 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
CN100358494C (zh) 1998-11-12 2008-01-02 弗兰克G·皮尔基威克兹 一种吸入给药系统
ATE331544T1 (de) 1999-05-28 2006-07-15 Nektar Therapeutics Gerät und verfahren zur aerosolisierung einer pharmazeutischen pulverzusammensetzung
ATE364381T1 (de) * 2000-04-17 2007-07-15 Vectura Ltd Formulierungen zur verwendung in inhalationsvorrichtungen
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6357490B1 (en) 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
WO2002054868A2 (en) 2000-12-21 2002-07-18 Inhale Therapeutic Syst Pulmonary delivery of polyene antifungal agents
US20040197271A1 (en) 2001-03-20 2004-10-07 Kunka Robert Leonard Inhalation drug combinations
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
EP1450885B1 (en) * 2001-09-28 2015-04-22 Kurve Technology, Inc. Nasal nebulizer
CA2482928A1 (en) * 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7334580B2 (en) 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
WO2004071368A2 (en) 2002-05-07 2004-08-26 The State University Of New York At Stony Brook Methods, devices and formulations for targeted endobronchial therapy
MXPA05007158A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceutica con un agente activo insoluble.
AU2004238217A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
AU2005245018A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
JP4931930B2 (ja) 2005-10-21 2012-05-16 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャネル阻害剤
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2668970B1 (en) 2006-10-25 2016-07-06 Novartis AG Powder dispersion apparatus
TW200840578A (en) * 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
EP2323648A4 (en) * 2008-08-14 2012-10-03 Uab Research Foundation AGAINST ARTHHYTHMIA, METHOD OF USE, IDENTIFICATION METHOD AND KITS THEREFOR
US8501727B2 (en) * 2008-08-22 2013-08-06 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
KR20160083953A (ko) * 2008-09-23 2016-07-12 라보라토리 스킨 케어, 인크. 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042467A1 (de) * 2005-10-10 2007-04-19 Boehringer Ingelheim International Gmbh Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2008066745A1 (en) * 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014012779; Ｂｏｒｌａｋ，Ｊ．　ｅｔ　ａｌ: 'Ｍｅｔａｂｏｌｉｓｍ　ｏｆ　ｖｅｒａｐａｍｉｌ　ｉｎ　ｃｕｌｔｕｒｅｓ　ｏｆ　ｒａｔ　ａｌｖｅｏｌａｒ　ｅｐｉｔｈｅｌｉａｌ　ｃｅｌｌｓ　ａｎｄ　ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ　ａｆｔｅｒ　ａｄｍｉ' Ｄｒｕｇ　Ｍｅｔａｂ　Ｄｉｓｐｏｓ Ｖｏｌ．　３３，　Ｎｏ．　８, 2005, ｐ．１１０８-１１１４ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015183006A (ja) * 2014-03-25 2015-10-22 リン, シン−ユンLin, Hsin−Yung 心疾患を治療するための吸入式医薬組成物及びその調製法
JP2019509985A (ja) * 2016-02-01 2019-04-11 インカーダ セラピューティクス， インコーポレイテッド 心房細動を含む心不整脈を管理するための吸入薬物療法との電子的監視の組み合せ
JP2020519628A (ja) * 2017-05-10 2020-07-02 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
JP2023100743A (ja) * 2017-05-10 2023-07-19 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
JP2021526900A (ja) * 2018-06-05 2021-10-11 インカーダ セラピューティクス， インコーポレイテッド エアロゾルを用いるブルガダ症候群の診断方法
JP2022533477A (ja) * 2019-08-01 2022-07-22 インカーダ セラピューティクス， インコーポレイテッド 抗不整脈製剤
JP7190077B2 (ja) 2019-08-01 2022-12-14 インカーダ セラピューティクス， インコーポレイテッド 抗不整脈製剤
JP2023022251A (ja) * 2019-08-01 2023-02-14 インカーダ セラピューティクス， インコーポレイテッド 抗不整脈製剤
JP7611211B2 (ja) 2019-08-01 2025-01-09 インカーダ セラピューティクス， インコーポレイテッド 抗不整脈製剤
JP2024502236A (ja) * 2020-12-17 2024-01-18 インカーダ セラピューティクス， インコーポレイテッド 心房性不整脈を有する対象におけるカルディオバージョンの誘導のためのキットおよび方法

Also Published As

Publication number Publication date
WO2010107964A1 (en) 2010-09-23
EP2413902A4 (en) 2014-02-19
EP3552603B1 (en) 2024-11-06
EP2413902B1 (en) 2019-07-17
PL2413902T3 (pl) 2020-01-31
US20150313842A1 (en) 2015-11-05
CA2835771A1 (en) 2010-09-23
JP7071949B2 (ja) 2022-05-19
ES3036464T3 (en) 2025-09-19
US8974828B2 (en) 2015-03-10
EP3552602B1 (en) 2025-03-05
EP3552603A1 (en) 2019-10-16
ES2750359T3 (es) 2020-03-25
EP3552602C0 (en) 2025-03-05
JP2017160268A (ja) 2017-09-14
CA2755809C (en) 2014-02-18
EP3552603C0 (en) 2024-11-06
ES3003038T3 (en) 2025-03-10
JP2019019139A (ja) 2019-02-07
US20120003318A1 (en) 2012-01-05
AU2010226613A1 (en) 2011-09-29
JP6715305B2 (ja) 2020-07-01
EP2413902A1 (en) 2012-02-08
AU2010226613B2 (en) 2013-07-25
US10045939B2 (en) 2018-08-14
DK2413902T3 (da) 2019-10-07
JP2015193657A (ja) 2015-11-05
CA2835771C (en) 2017-01-24
US20190060230A1 (en) 2019-02-28
US20180296480A1 (en) 2018-10-18
JP2019203032A (ja) 2019-11-28
US20180318213A1 (en) 2018-11-08
CA2755809A1 (en) 2010-09-23
EP3552602A1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
JP6715305B2 (ja) 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2023100743A (ja) 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
AU2013248242B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
JP2024502236A (ja) 心房性不整脈を有する対象におけるカルディオバージョンの誘導のためのキットおよび方法
ES3040411T3 (en) A novel method to slow ventricular rate
AU2016256776B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CN116867483A (zh) 用于诱导患有房性心律失常的对象的心脏复律的试剂盒和方法
HK40013847B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013847A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140725

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150729

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150925

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150929